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Gallic Acid and Methyl Gallate Enhance Antiproliferative Effect of Cisplatin on 
Cervical Cancer (HeLa) Cells 
(Asid Galik dan Metil Galat Mempertingkat Kesan Antiproliferatif Cisplatin ke atas Sel Kanser Serviks (HeLa))




Cervical cancer is the fourth most common cancer-related death affecting women. The drug resistance, toxicities and 
undesired side effects become the major limitation in cisplatin-based chemotherapy. Gallic acid and methyl gallate 
are the most abundance phenolic compounds that are widely distributed in plants. This study was conducted to 
evaluate the antioxidant and antiproliferative activity of gallic acid and methyl gallate and their synergistic effects in 
combination with cisplatin towards cervical cancer (HeLa) cells. The antioxidant activity of gallic acid and methyl 
gallate was measured by using 1, 1-diphenyl-2-picrylhydrazyl radical (DPPH) scavenging assay. Antiproliferative 
activity of gallic acid, methyl gallate and cisplatin on HeLa and NIH/ 3T3 cells was determined using MTT assay. 
The effect of gallic acid and methyl gallate combined with cisplatin were then determined by CompuSyn software. 
Gallic acid and methyl gallate showed strong antioxidant activity with EC50 value of 18.23 µM and 19.39 µM, 
respectively. The IC50 of gallic acid, methyl gallate and cisplatin on HeLa cells were 13.44 µg/mL, 16.55 µg/mL, and 
8.04 µg/mL whereas in NIH/3T3 cells were 32.90 µg/mL, 35.70 µg/mL, and 6.57 µg/mL. Cisplatin combined with 
fixed concentration of gallic acid and methyl gallate could inhibit the proliferation of HeLa cells greater than cisplatin 
alone. Interestingly, gallic acid and methyl gallate in combination with cisplatin at the concentration of 0.51-4.02 µg/
mL have shown synergistic effects. Therefore, our study suggested that gallic acid and methyl gallate in combination 
with cisplatin have the potential to be developed as chemotherapeutic agents for cervical cancer.
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 ABSTRAK
Kanser serviks merupakan kanser keempat yang paling kerap dihidapi dalam kalangan wanita. Faktor kerintangan, 
kesan toksik dan kesan sampingan yang tidak diingini mengehadkan penggunaan cisplatin dalam rawatan kanser. 
Asid galik dan metil galat merupakan fenolik yang paling banyak ditemui dalam tumbuhan. Kajian ini dijalankan 
untuk menilai aktiviti antioksidan dan akiviti antiproliferatif asid galik dan metil galat dan kesan sinergi kombinasinya 
dengan cisplatin ke atas sel kanser serviks (HeLa). Aktiviti antioksidan asid galik dan metil galat ditentukan dengan 
asai hapus-sisa radikal bebas DPPH. Manakala aktiviti antiproliferatif ke atas sel HeLa dan NIH/3T3 ditentukan 
melalui asai MTT. Kesan kombinasi antara asid galik dan metil galat dengan cisplatin ditentukan dengan perisian 
CompuSyn. Asid galik dan metil galat menunjukkan aktiviti antioksidan yang kuat dengan nilai EC50 masing-masing 
adalah 18.23 µM dan 19.39 µM. IC
50,
 bagi asid galik, metil galat dan cisplatin ke atas sel HeLa pula adalah 13.44 
µg/mL, 16.55 µg/mL dan 8.04 µg/mL manakala pada sel NIH/ 3T3 adalah 32.90 µg/mL, 35.70 µg/mL dan 6.57 µg/mL. 
Kombinasi antara cisplatin dan asid galik serta metil galat pada kepekatan tertentu berupaya merencat pertumbuhan 
sel HeLa dengan lebih cekap berbanding dengan rawatan cisplatin sahaja. Kombinasi asid galik dan metil galat 
dengan cisplatin pada kepekatan 0.51-4.02 µg/mL juga telah menunjukkan kesan sinergi. Oleh itu, kombinasi asid galik 
dan metil galat dengan cisplatin berpotensi untuk dibangunkan sebagai agen rawatan kemoterapi untuk kanser serviks.
Kata kunci: Aktiviti antioksidan; aktiviti antiproliferatif; asid galik; kesan sinergi; metil galat
INTRODUCTION
Cancer is one of the death-leading causes worldwide 
and becomes a serious problem affecting human health. 
Apart from that, cervical cancer is the most common 
type of cancer among women. According to GLOBOCAN 
2012, cervical cancer is the fourth most common cancer 
in women and the seventh from the overall cancers. It 
represents about 7.5% of female cancer deaths which 
numbered approximately 266,000 deaths from cervical 
cancer worldwide. Additionally, majority of these cervical 
cancer deaths mostly occur in less developed regions 
(Ferlay et al. 2013). It also becomes the leading cause of 
cancer-related deaths among women in Eastern, Western 
and Middle Africa; Central America; South-Central Asia 
and Melanesia (Arbyn et al. 2011). According to Malaysian 
National Cancer Registry Report 2007-2011, cervical 
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cancer was the third common cancer in women with 7.7% 
cases and age standardised incidence rate of 7.6 per 100000. 
Cervical cancer incidence rate increased from the age of 
30 years old and peaked at 65-69 years old. Generally, 
the incidence was the highest among Chinese, followed 
by Malays and Indians. The most aetiological factor 
associated with cervical cancer is human pappilomavirus 
(HPV) infection which is commonly from HPV type 16 
and HPV type 18 (Muhamad et al. 2015). Despite screening 
and HPV vaccination among women have reduced the 
incidence and mortality rates in developed country, there 
are still many young women who are newly diagnosed 
each year (Gordon et al. 2018). 
Cisplatin is a well known chemotherapeutic drug, 
clinically used to treat various types of cancers. In 1978, 
cisplatin has been approved by FDA as a leading anti-
cancer drug for several types of cancer including bladder 
cancer, cervical cancer, ovarian cancer, testicular cancer, 
non-small cell lung cancer and squamous cell carcinoma 
of the head & neck (Purena et al. 2018). Its anticancer 
effect is mainly achieved through DNA damaging 
activity, resulting in the DNA adduct formation (Selvi 
et al. 2017). Cisplatin is given based on its emetogenic 
potential which is a function of its dose. Cisplatin is 
considered as having high emetogenic potential at the dose 
of  ≥50 mg/m2  and moderate emetogenic potential at <50 
mg/m2 (Karpe et al. 2016). Cisplatin has been used either 
individually or combined with other chemotherapeutic 
drugs. Currently, the administration of various regimens 
are given to the cancer patients based on cancer type and 
the severity of the disease (Higuchi & Yanagawa 2019).
Although this agent is generally effective, its use 
has been limited due to its toxicity and resistance by the 
cancer cells. Cisplatin treatment causes nephrotoxicity, 
hepatotoxicity, and cardiotoxicity to the patients (Dasari 
& Bernard 2014). Therefore, one of the approaches to 
overcome these problems is combination chemotherapy, 
in which other therapeutic agents are combined with 
chemotherapeutic drug. The combination chemotherapy 
has better effects as it can sensitise cancer response to 
drugs, act towards cancer through different signalling 
pathway and lower the drug dose (Qin et al. 2018). 
In the recent years, there is an increase of interest 
among researchers to explore the potential of natural 
antioxidants as therapeutic agents towards cancer and 
other health problems. Alternative substances from 
natural product sources with high antioxidant properties 
are reported to exhibit anticancer activities. These 
antioxidants may reduce or prevent many side effects 
contributed by reactive oxygen species generated by 
chemotherapy (Conklin 2000).
Gallic acid (3,4,5-trihydroxybenzoic acid, GA) 
and its methyl ester derivative, methyl gallate (methyl 
3,4,5-trihydroxybenzoate, MG) as shown in Figure 1 
are the common phenolic compounds found in various 
plants (Farhoosh & Nystrom 2018). Gallic acid exists in 
red wine, green tea, strawberries, pineapples, bananas, 
lemons, gallnuts, sumac, witch hazel, tea leaves, oak 
bark, and apple peels (Asci et al. 2017). The distribution 
of methyl gallate on the other hand is mostly abundant 
in Meliaceae species, Galla Rhois, Rosa rugosa, 
Terminalia myriocarpa, and Geranium niveum and 
in maple (Genus acer) leaves, grape seeds, and seed 
kernels of Mangifera indica L. (Jeon et al. 2016). Various 
biological activities of GA and MG have been reported 
in previous studies. GA exhibits antioxidant and anti-
inflammatory effects by protecting human cells or 
tissues against oxidative stress (Asci et al. 2017). GA 
is also reported to have antidiabetic (Oboh et al. 2016) 
and antimicrobial activity (Chanwithesuk et al. 2007). 
In addition, antiproliferative effects by GA and MG have 
been reported in different cell lines (Heidarian 2017; 
Kamatham et al. 2015; Lu et al. 2010; Nam et al. 2016;). 
To the best of our knowledge, the antiproliferative 
effect of gallic acid and methyl gallate combined with 
cisplatin on HeLa still have not been reported. Thus, 
in the present study, GA and MG were evaluated for 
their antioxidant activities. GA and MG combined with 
chemotherapeutic drug, cisplatin were also evaluated for 
the antiproliferative effects towards HeLa cancer cells. 
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Dulbecco’s modified Eagle’s medium (DMEM), fetal 
bovine serum, trypsin, streptomycin, and penicillin 
were purchased from Gibco Thermo scientific. 
3-(4,5-dimethylthiazol-2-yl)-2, 5 diphenyltetrazolium 
bromide (MTT) was purchased from Nacalai Tesque, 
Inc. (Japan), dimethyl sulfoxide (DMSO), 2,2-diphenyl-1-
picrylhydrazyl (DPPH), gallic acid, methyl gallate, and 
cisplatin were purchased from Sigma Chemical Co. (St. 
Louis, MO, USA).
1, 1-DIPHENYL-2-PICRYLHYDRAZYL (DPPH) RADICAL 
SCAVENGING ASSAY
The color changes of DPPH solution by reducing 
amount of hydrogen donating compounds was used for 
evaluating antioxidant activity. The scavenging activity 
of GA and MG were evaluated based on the method as 
described by Alma et al. (2003) with slight modification. 
Briefly, the various concentrations of GA and MG were 
prepared by diluting the compounds in methanol. 2 mL 
of the compounds solution were then added with 2 mL 
of 0.3 mM DPPH solution in methanol. The reaction 
tubes, in triplicates, were wrapped in aluminum foil and 
kept at room temperature for 30 min in dark. Then, the 
absorbance was measured at 517 nm using a UV-VIS 
spectrophotometer. Ascorbic acid solution was used as a 
positive control. The scavenging activity was calculated 
using the following equation:
whereby A1 is the absorbance of negative control; and 
A0 is the absorbance of DPPH solution with sample 
solution.
CELL CULTURE
HeLa (ATCC CCL-2) and NIH/3T3 (ATCC CRL-1658) 
cells were purchased from American Type Culture 
Collection (ATCC). The HeLa and NIH/3T3 cells used 
in this study were in passage 10-20. The cell lines were 
grown in humidified atmosphere under the condition of 
37 °C with 5% (v/v) CO2. The complete medium used 
for culturing cells was the mixture of DMEM, 10% FBS 
and 1% penicillin-streptomycin. 
PREPARATION OF COMPOUND TREATMENTS
Cisplatin, GA, and MG stock solution (10 mg/mL) were 
prepared by diluting 10 mg of compounds in 1 mL of 
DMSO. The solution was filtered by using 0.2 µL sterile 
filter unit. The stock solution was then further diluted 
with culture medium to the different concentrations 
(100, 50, 25, 12.5, 6.25, 3.125, 1.56, 0.781, and 0.39 µg/
mL) prior to use.
CYTOTOXICITY DETERMINATION USING MTT ASSAY
HeLa cells (3 × 103 cells per well) and NIH/3T3 cells 
(4 × 103 cells per well) were seeded in 96 well plates. 
The cells were incubated at 37 °C. After 24 h, cells were 
treated with 100 µL of gallic acid, methyl gallate and 
cisplatin as a positive control at various concentrations 
(100, 50, 25, 12.5, 6.25, 3.125, 1.56, 0.781, and 0.391 
µg/mL). The treated cells were incubated for 72 hours 
in 37 °C CO2 incubator. Then, 10 uL of MTT (5 mg/
mL in PBS) was added to each well and incubated for 
additional 4 h at 37 °C. The culture medium was removed 
and 100 µL of DMSO was added to each well to dissolve 
the purple-blue formazan crystals. The absorbance (OD) 
was read at 570 nm using ELISA reader. IC50 of cisplatin, 
gallic acid and methyl gallate were calculated from the 
dose response curve by plotting a graph of percent of cell 
viability against log concentration. The percentage of cell 
viability is based on the following formula:
  (OD value of treated cell/OD value of untreated cells) × 100.
ANALYSIS OF SYNERGISTIC EFFECTS
To determine the combination effects of GA and MG 
with cisplatin, a non-constant combination treatment 
of compounds (GA and MG) and cisplatin was done 
following the method as described by Omar et al. 
(2016) with slight modification. The HeLa cells were 
treated with cisplatin at various concentrations (8.04, 
4.02, 2.01, 1.01, and 0.5 µg/mL) in combination with 
fixed concentration, IC50 value of GA at 13.44 µg/mL 
and IC50 value of MG at 16.55 µg/mL. The data from this 
experiment were analysed using CompuSyn software 
to determine the combination effects of the drugs 
combination. The statistical analysis was performed 
and the results were expressed as combination index 
(CI). A CI value is a mathematical and quantitative 
representation of the pharmacological interaction of 
two drugs (Cl >1: antagonism; Cl=1: additive; CI <: 
synergism).
STATISTICAL ANALYSIS
All values were represented as the mean ± SD. The 
differences in the mean and IC50 were analysed using 
Graph Pad Prism version 6. Combination index (CI) 
of the drug combinations was determined using 
CompuSyn Software. 
RESULTS AND DISCUSSION
1-DIPHENYL-2-PICRYLHYDRAZYL (DPPH) RADICAL 
SCAVENGING ASSAY
Recently, natural antioxidants have attracted great interest 
among researchers because of their safety properties. 
GA and its derivatives that belong to the phenolic acids 
DPPH radical scavenging (%)   =    (A1 − A0A1 )      ×  100                                  
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group are naturally occurring antioxidants that are 
widely distributed in plants. They have also been used 
widely in pharmaceuticals and food industries in which 
most of them are identified as efficient DPPH radical 
scavenger (Kalita et al. 2012). Phenolic acids are known 
as strong antioxidants and can scavenge free radicals 
due to their hydroxylated molecular properties (Sevgi et 
al. 2015). Previous study conducted by Karamac et al. 
(2005) shows that GA is the most effective compound 
in scavenging the DPPH radicals compared to other 
phenolic acids compounds. The differences in scavenging 
activities between these phenolic acids are attributed to 
the different number of hydroxyl moieties attached to the 
aromatic ring of the benzoic or cinnamic acid molecules. 
Our study showed that GA and MG exhibited very potent 
anti-radical scavenging activities (Figure 2). Both of the 
compounds showed concentration-dependent manner in 
a dose response curve. GA exhibited a slightly higher 
antioxidant activity with EC50 value of 18.23 µM compared 
to MG (EC50 19.39 µM). The similar findings have also 
been reported Asnaashari et al. (2014), Kikuzaki et 
al. (2002), and Lu et al. (2006). The result reveals that 
although these phenolic acids have the same number of 
hydroxyl groups, GA with an additional carboxylic group 
in its molecules is found to be more active than methyl 
gallate which contains carboxylic acid ester group 
(Kikuzaki et al. 2002). 
CYTOTOXICITY EFFECT 
The antiproliferative activity of GA and MG towards 
HeLa and NIH/3T3 cells was evaluated using MTT 
assay. Figure 3 shows the antiproliferative activity of 
GA, MG and cisplatin as a positive control towards 
HeLa cells and NIH/3T3 cells. GA and MG were shown 
to inhibit cell growth of both cancer and normal cells. 
HeLa and NIH/3T3 cells growth were inhibited by GA 
and MG in a dose-dependent manner. The IC50 of GA, 
MG, and cisplatin on HeLa were 13.44, 16.55, and 8.04 
µg/mL, respectively, whereas in NIH cells the IC50 of 
GA, MG and cisplatin were 32.90, 35.70, and 6.57 µg/
mL, respectively. The different antiproliferative effects 
seen in cancer and normal cells indicates that GA and 
MG exhibit less cytotoxicity effect and are safe in normal 
NIH/3T3 cells compared to HeLa cells. The lower IC50 
value of GA and MG may suggest that these compounds 
could be considered as effective anticancer agents 
towards HeLa cells. The similar antiproliferative effects 
of GA on HeLa had also been reported previously (Park 
2017; You et al. 2010; Zhao & Hu 2013). 
Over the years, cisplatin is known as an effective 
antineoplastic agent and has been widely used to treat 
numerous types of cancer cell. In this study, the low IC50 
value of cisplatin in HeLa and NIH/3T3 cells indicates 
that cisplatin is not only cytotoxic to cancer cells but 
it is also harmful to the normal cells. Cisplatin can 
activate apoptotic pathways and lead to cellular damage 
in normal tissue through induction of oxidative stress 
and inflammation. Although many strategies have been 
developed to overcome this problem, the data and 
clinical trials are still lacking. Thus, despite inducing 
organ toxicities and developing cell resistance, cisplatin 
still remains as the most frequent drug used in cancer 
treatment (Sun et al. 2019).  
FIGURE 2. DPPH radical scavenging activity of GA and MG at different concentrations. Each value represents 
the mean ± SD (n=3)
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Recently, the new alternative strategy involving the 
combination of phytochemical compounds and 
anticancer drugs has been developed. Currently, 
phytochemicals derived from plants are actively 
discovered with more than 10,000 phytochemicals have 
been identified and used in cancer treatment (Tuorkey 
2015). The combination of active compounds with 
anticancer drugs might produce synergistic, antagonistic 
and additive effects. The beneficial effects of synergism 
are that this combination strategy could synergise the 
efficacy of drugs and decrease the drugs dosage; thus 
can reduce their toxicity (Koraneekit et al. 2018). 
In this study, the effect of GA and MG combined 
with cisplatin on HeLa cells was determined by a non-
constant combination treatment. Serial concentrations 
of cisplatin were combined with fixed concentration of 
gallic acid at 13.44 µg/mL and methyl gallate at 16.55 µg/
mL. Overall, GA in combination with cisplatin inhibited 
around 70% of cell proliferation while the combination 
of MG and cisplatin inhibited 50% of cell proliferation 
at all concentrations. Higher cells inhibition was seen 
in combination of GA and MG compared to cisplatin 
alone (Figure 4). These combinations effects were then 
evaluated using CompuSyn Software. Table 1 shows the 
Cl values of different combination of GA and MG with 
cisplatin. The combinations of GA and cisplatin at 0.51 
µg/mL to 4.02 µg/mL demonstrated CI values of less than 
1 which were between 0.2626 and 0.4386, indicating 
that all these combinations had synergistic effects. The 
lowest CI value was shown by the combination of GA 
and cisplatin at 0.51 µg/mL. Only the combination of 
GA and cisplatin at 8.04 µg/mL showed an antagonistic 
effect with the CI value of 1.014. On the other hand, 
the different combinations of MG and cisplatin showed 
the CI values in between 0.3229 to 1.394 (Table 2). All 
combinations showed CI values less than 1 except for 
the combination of MG and cisplatin at 8.04 µg/mL. 
The lowest CI value was exhibited by the combination 
of MG and cisplatin at 0.51 µg/mL. Greater HeLa cells 
inhibition was seen in the combination of GA and MG 
with cisplatin, showing that these combinations could 
enhance cisplatin’s effect. The reported CI values of less 
than 1 indicate that GA and MG interact synergistically 
FIGURE 3. Antiproliferative activity of different concentration of GA and MG on HeLa 
cells (A) and NIH/3T3 cells (B). Each value represents the mean ± SD from three separate 
experiments
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with cisplatin, inhibiting HeLa cells’ proliferation. These 
combinations might induce DNA damage in cells and 
activate the intra-S-phase checkpoint to inhibit DNA 
synthesis, resulting in apoptosis or cellular senescence. 
However, further investigation is needed.
GA in combination with cisplatin has been 
reported to enhance anticancer effect and apoptosis on 
human small cell lung cancer cells (Wang et al. 2016). 
This combination is also found to increase tumor cell 
apoptosis of lung cancer in mice (Kawada et al. 2001). In 
addition, other study has shown that the combination of 
MG and cisplatin shows stronger anti-cancer effects on 
EL4 murine lymphoma than MG or cisplatin alone (Kim 
et al. 2016).
However, this in-vitro cytotoxicity study had 
several limitations. The cultured cells growing in-vitro 
are not exactly the same as the dissociated replicates of 
the cells in-vivo. Other factors may affect the cytotoxic 
effect of the compounds in-vivo such as metabolism and 
pharmacokinetics in which it is impossible to stimulate 
these parameters in-vitro. Therefore, it is necessary to 
further investigate the effect of the compound in future 
in-vivo study. 
TABLE 1. CI values for combination effect of cisplatin and GA on HeLa cells























TABLE 2. CI values for combination effect of cisplatin and MG on HeLa cells























FIGURE 4. The antiproliferative effect of cisplatin alone and cisplatin in combination with GA and MG on 
HeLa cells. Each value represents mean ± SD from three separate experiments. ****: p<0.0001 







































The result of this present study demonstrated that GA 
and MG in combination with cisplatin synergistically 
inhibited the growth of HeLa cells even at lower 
concentration of cisplatin. This finding may suggest 
that GA and MG are potential sources that can be used 
in combination with cisplatin for the development 
of new therapeutic agents for cancer treatment. The 
outcome of this study also provides the basis for the 
molecular studies to find the exact mechanism on how 
the combinations act synergistically towards HeLa cells.
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